Frédéric Triebel

This inventor holds 7 USPTO granted patents and 4 published patent applications and 16 EPO patents. Top assignees: Immutep S.a.s., Novartis Ag, Institut Gustave Roussy. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frédéric Triebel. Retrieved from https://idiyas.com/inventor/frédéric-triebel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 85.7

EPO Patents = 16 (Patent Applications = 25)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 63(Granted Patents)

Company Filing History:

Institut Gustave Roussy

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252535 - Antibody molecules to LAG-3 and uses thereof (2025-03-18),

2. 11680104 - Anti-LAG-3 antibodies (2023-06-20),

3. 10711060 - Antibody molecules to LAG-3 and uses thereof (2020-07-14),

4. 9908936 - Antibody molecules to LAG-3 and uses thereof (2018-03-06),

5. 9579382 - Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response (2017-02-28),

6. 6875844 - Peptide compounds derived from a shifted ORF of the iCE gene (2005-04-05),

7. 6855802 - Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy (2005-02-15),

Title: Frédéric Triebel: Innovator in Antibody Molecules

Introduction

Frédéric Triebel is a prominent inventor based in Versailles, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibody molecules. With a total of 7 patents to his name, Triebel's work has the potential to impact the treatment of various diseases, including cancer and autoimmune disorders.

Latest Patents

Triebel's latest patents focus on antibody molecules that specifically bind to LAG-3, a protein involved in immune regulation. One of his notable inventions is an antibody molecule that can be used to treat, prevent, and diagnose cancerous or infectious disorders. Additionally, he has developed bispecific antibody molecules that target both LAG-3 and other proteins such as PD-1 and PD-L1. These innovations aim to enhance the immune response against tumors and improve therapeutic outcomes for patients.

Career Highlights

Throughout his career, Frédéric Triebel has worked with leading companies in the pharmaceutical industry, including Immutep S.a.s. and Novartis AG. His expertise in antibody development has positioned him as a key figure in advancing therapeutic strategies for immune-related conditions. Triebel's innovative approach has garnered attention and respect within the scientific community.

Collaborations

Triebel has collaborated with notable professionals in his field, including Chrystelle Brignone and Walter A. Blattler. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in biotechnology.

Conclusion

Frédéric Triebel's contributions to the field of antibody molecules demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight his role as a leading inventor in the biotechnology sector. Through his work, Triebel continues to pave the way for new therapeutic options that could benefit countless patients worldwide.

Profile summary based on public USPTO records.